Duloxetine to Prevent Oxaliplatin-induced Chemotherapy Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Alliance A221805)
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
Principal Investigator(s)
Salvatore Del Prete, MD
Sponsor(s)
Alliance for Clinical Trials in Oncology
Contact
Ed Hatton, RN at 203-358-8879 or [email protected]
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695
Stamford, CT 06902
Main: 203-276-2695